Cargando…
Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
To characterize the immunogenicity of mRNA-1273 (Moderna, Cambridge, MA, USA) vaccine in HIV-positive hemophilic patients during the third COVID-19 wave in Italy and to investigate biomarkers of coagulation and endothelial perturbation before and after complete vaccination schedule, twenty-three con...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487950/ https://www.ncbi.nlm.nih.gov/pubmed/37685542 http://dx.doi.org/10.3390/jcm12175475 |
_version_ | 1785103362956460032 |
---|---|
author | Suffritti, Chiara Gualtierotti, Roberta Arcudi, Sara Ciavarella, Alessandro Novembrino, Cristina Lecchi, Anna La Marca, Silvia Padovan, Lidia Scalambrino, Erica Clerici, Marigrazia Bono, Patrizia Ceriotti, Ferruccio Muscatello, Antonio Siboni, Simona Maria Peyvandi, Flora |
author_facet | Suffritti, Chiara Gualtierotti, Roberta Arcudi, Sara Ciavarella, Alessandro Novembrino, Cristina Lecchi, Anna La Marca, Silvia Padovan, Lidia Scalambrino, Erica Clerici, Marigrazia Bono, Patrizia Ceriotti, Ferruccio Muscatello, Antonio Siboni, Simona Maria Peyvandi, Flora |
author_sort | Suffritti, Chiara |
collection | PubMed |
description | To characterize the immunogenicity of mRNA-1273 (Moderna, Cambridge, MA, USA) vaccine in HIV-positive hemophilic patients during the third COVID-19 wave in Italy and to investigate biomarkers of coagulation and endothelial perturbation before and after complete vaccination schedule, twenty-three consecutive adult HIV-positive patients with hemophilia were included. Blood was collected before and two weeks after vaccination. We measured anti-SARS-CoV-2 spike protein antibodies to assess immunogenicity; circulating biomarkers of coagulation (protein C and D-dimer), endothelial perturbation (von Willebrand factor (VWF)) and anti-Platelet Factor 4 (PF4) antibodies were analyzed. Flow-based analysis of thrombus formation was performed in nine patients using a flow-chamber device. Two weeks after completing the vaccination schedule, all patients had anti-spike antibodies values consistent with an effective immunization. Mean (±standard deviation) basal values of protein C and VWF (106 ± 21% and 171 ± 45%, respectively) were not significantly different from data obtained two weeks after the second dose (103 ± 20%, 162 ± 43%, respectively). D-dimer median values (interquartile range) were not significantly different at baseline (442 (603–142) ng/mL) and after the second dose (477 (654–262) ng/mL). Anti-PF4 antibodies were detected in three patients with no associated clinical manifestations. No significant differences were found in flow-based analysis of thrombus formation. Our data demonstrate that in HIV-positive patients with hemophilia, SARS-CoV-2 vaccination is effective and safe, with no effects on coagulation and endothelial perturbation. |
format | Online Article Text |
id | pubmed-10487950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104879502023-09-09 Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study Suffritti, Chiara Gualtierotti, Roberta Arcudi, Sara Ciavarella, Alessandro Novembrino, Cristina Lecchi, Anna La Marca, Silvia Padovan, Lidia Scalambrino, Erica Clerici, Marigrazia Bono, Patrizia Ceriotti, Ferruccio Muscatello, Antonio Siboni, Simona Maria Peyvandi, Flora J Clin Med Brief Report To characterize the immunogenicity of mRNA-1273 (Moderna, Cambridge, MA, USA) vaccine in HIV-positive hemophilic patients during the third COVID-19 wave in Italy and to investigate biomarkers of coagulation and endothelial perturbation before and after complete vaccination schedule, twenty-three consecutive adult HIV-positive patients with hemophilia were included. Blood was collected before and two weeks after vaccination. We measured anti-SARS-CoV-2 spike protein antibodies to assess immunogenicity; circulating biomarkers of coagulation (protein C and D-dimer), endothelial perturbation (von Willebrand factor (VWF)) and anti-Platelet Factor 4 (PF4) antibodies were analyzed. Flow-based analysis of thrombus formation was performed in nine patients using a flow-chamber device. Two weeks after completing the vaccination schedule, all patients had anti-spike antibodies values consistent with an effective immunization. Mean (±standard deviation) basal values of protein C and VWF (106 ± 21% and 171 ± 45%, respectively) were not significantly different from data obtained two weeks after the second dose (103 ± 20%, 162 ± 43%, respectively). D-dimer median values (interquartile range) were not significantly different at baseline (442 (603–142) ng/mL) and after the second dose (477 (654–262) ng/mL). Anti-PF4 antibodies were detected in three patients with no associated clinical manifestations. No significant differences were found in flow-based analysis of thrombus formation. Our data demonstrate that in HIV-positive patients with hemophilia, SARS-CoV-2 vaccination is effective and safe, with no effects on coagulation and endothelial perturbation. MDPI 2023-08-23 /pmc/articles/PMC10487950/ /pubmed/37685542 http://dx.doi.org/10.3390/jcm12175475 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Suffritti, Chiara Gualtierotti, Roberta Arcudi, Sara Ciavarella, Alessandro Novembrino, Cristina Lecchi, Anna La Marca, Silvia Padovan, Lidia Scalambrino, Erica Clerici, Marigrazia Bono, Patrizia Ceriotti, Ferruccio Muscatello, Antonio Siboni, Simona Maria Peyvandi, Flora Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study |
title | Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study |
title_full | Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study |
title_fullStr | Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study |
title_full_unstemmed | Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study |
title_short | Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study |
title_sort | characterization of immunogenicity and safety of covid-19 mrna-1273 in hiv-positive italian patients with hemophilia: a prospective single-center cohort study |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487950/ https://www.ncbi.nlm.nih.gov/pubmed/37685542 http://dx.doi.org/10.3390/jcm12175475 |
work_keys_str_mv | AT suffrittichiara characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT gualtierottiroberta characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT arcudisara characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT ciavarellaalessandro characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT novembrinocristina characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT lecchianna characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT lamarcasilvia characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT padovanlidia characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT scalambrinoerica characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT clericimarigrazia characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT bonopatrizia characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT ceriottiferruccio characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT muscatelloantonio characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT sibonisimonamaria characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy AT peyvandiflora characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy |